12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Erivedge vismodegib regulatory update

Curis said partner Roche submitted a regulatory application to Australia's Therapeutic Goods Administration ( TGA) for Erivedge vismodegib to treat advanced basal cell carcinoma (BCC) in adults who are not candidates for surgery. The submission triggers a $4...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >